Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, April 29, 2026, 17:15 GMT-04
NovoNordisk-FRONTIER2
Read full article →